Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 13/20 | 0.73 |
| ▸ | FGFR4 | P22455 | 9/20 | 0.73 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.73 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.73 |
| ▸ | JAK2 | O60674 | 2/20 | 0.73 |
| ▸ | ABL1 | P00519 | 2/20 | 0.73 |
| ▸ | INSR | P06213 | 2/20 | 0.73 |
| ▸ | LCK | P06239 | 2/20 | 0.73 |
| ▸ | FYN | P06241 | 2/20 | 0.73 |
| ▸ | YES1 | P07947 | 2/20 | 0.73 |
| ▸ | LYN | P07948 | 2/20 | 0.73 |
| ▸ | RET | P07949 | 2/20 | 0.73 |
| ▸ | MET | P08581 | 2/20 | 0.73 |
| ▸ | ROS1 | P08922 | 2/20 | 0.73 |
| ▸ | KIT | P10721 | 2/20 | 0.73 |
| ▸ | SRC | P12931 | 2/20 | 0.73 |
| ▸ | BRAF | P15056 | 2/20 | 0.73 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.73 |
| ▸ | FLT1 | P17948 | 2/20 | 0.73 |
| ▸ | TYK2 | P29597 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Infigratinib SCHEMBL374435 | 0.85 | FGFR3 (1.00) | FGFR3FGFR4FGFR1FGFR2JAK2 | |
| SCHEMBL2017841 | 0.84 | FGFR3 (0.84) | FGFR3FGFR4FGFR1FGFR2JAK2 | |
| SCHEMBL19588439 | 0.83 | FGFR3 (0.77) | FGFR3FGFR4FGFR1FGFR2JAK2 | |
| Infigratinib SCHEMBL14893408 | 0.82 | FGFR3 (1.00) | FGFR3FGFR4FGFR1FGFR2JAK2 | |
| SCHEMBL2013451 | 0.82 | FGFR3 (0.91) | FGFR3FGFR4FGFR1FGFR2JAK2 | |
| SCHEMBL2011033 | 0.82 | FGFR3 (0.91) | FGFR3FGFR4FGFR1FGFR2JAK2 | |
| SCHEMBL19338005 | 0.82 | FGFR3 (0.91) | FGFR3FGFR4FGFR1FGFR2JAK2 | |
| SCHEMBL16383021 | 0.81 | FGFR3 (0.92) | FGFR3FGFR4FGFR1FGFR2JAK2 | |
| SCHEMBL23281490 | 0.80 | FGFR3 (0.91) | FGFR3FGFR4FGFR1FGFR2JAK2 | |
| SCHEMBL19848824 | 0.80 | FGFR3 (0.84) | FGFR3FGFR4FGFR1FGFR2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4340840-A1 | FGFR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF ADVANCED SOLID TUMORS | JANSSEN Pharmaceutica NV (BE) | 2024-03-27 | — | — | EP | disclosed |
| CN-117320724-A | FGFR tyrosine kinase inhibitor for treating advanced solid tumor | 詹森药业有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-116669763-A | FGFR inhibitor combination therapy | 詹森药业有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-4210702-A1 | FGFR INHIBITOR COMBINATION THERAPIES | JANSSEN Pharmaceutica NV (BE) | 2023-07-19 | — | — | EP | disclosed |
| EP-4204021-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | Advanced Accelerator Applications International S.A. (CH) | 2023-07-05 | — | — | EP | disclosed |
| EP-4103184-A1 | FGFR TYROSINE KINASE INHIBITORS AND ANTI-PD1 AGENTS FOR THE TREATMENT OF UROTHELIAL CARCINOMA | Janssen Pharmaceutica NV (BE) | 2022-12-21 | — | — | EP | disclosed |
| CN-115103678-A | FGFR tyrosine kinase inhibitors for the treatment of high risk non-muscle invasive bladder cancer | 詹森药业有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-115087446-A | FGFR tyrosine kinase inhibitor and anti-PD 1 agent for treating urothelial cancer | 詹森药业有限公司 | 2022-09-20 | — | — | CN | disclosed |
| EP-3946340-A1 | FGFR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF UROTHELIAL CARCINOMA | Janssen Pharmaceutica NV (BE) | 2022-02-09 | — | — | EP | disclosed |
| EP-3946341-A1 | FGFR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF UROTHELIAL CARCINOMA | Janssen Pharmaceutica NV (BE) | 2022-02-09 | — | — | EP | disclosed |
| CN-113645975-A | FGFR tyrosine kinase inhibitors for the treatment of urothelial cancer | 詹森药业有限公司 | 2021-11-12 | — | — | CN | disclosed |
| WO-2021160763-A1 | FGFR TYROSINE KINASE INHIBITORS AND ANTI-PD1 AGENTS FOR THE TREATMENT OF UROTHELIAL CARCINOMA | JANSSEN PHARMACEUTICA NV (BE) | 2021-08-19 | — | — | WO | disclosed |
| WO-2020205493-A1 | FGFR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF UROTHELIAL CARCINOMA | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020201138-A1 | FGFR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF UROTHELIAL CARCINOMA | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-08 | — | — | WO | disclosed |
| EP-3645018-A1 | NANODIAMONDS AS ARTIFICIAL PROTEINS FOR REGULATION OF A CELL SIGNALLING SYSTEM | Ustav organicke chemie a biochemie AV CR, v.v.i. (CZ) | 2020-05-06 | — | — | EP | disclosed |
| EP-3642240-A1 | ANTIBODY MOLECULES TO CD73 AND USES THEREOF | Novartis AG (CH) | 2020-04-29 | — | — | EP | disclosed |
| WO-2019185667-A1 | NANODIAMONDS AS ARTIFICIAL PROTEINS FOR REGULATION OF A CELL SIGNALLING SYSTEM | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V. V. I. (CZ) | 2019-10-03 | — | — | WO | disclosed |
| WO-2018237173-A1 | ANTIBODY MOLECULES TO CD73 AND USES THEREOF | NOVARTIS AG (CH) | 2018-12-27 | — | — | WO | disclosed |
| WO-2018049233-A9 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 4 IN COMBINATION WITH CYCLIN-DEPENDENT KINASE INHIBITORS | STRANSKY NICOLAS (US) | 2018-07-12 | — | — | WO | disclosed |
| WO-2018049233-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR IN COMBINATION WITH CYCLIN-DEPENDENT KINASE INHIBITORS | STRANSKY NICOLAS (US) | 2018-03-15 | — | — | WO | disclosed |